EAST SETAUKET, N.Y., April 4, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. announced receiving an official notice of allowance from the United States Patent and Trademark Office for its lead histone deacetylase inhibitor (HDACi), LB-201 and other structural homologs.
Dr. John Kovach, founder and president of Lixte, said, "Although there are HDACi approved for certain types of skin lymphomas and many other HDACi in various stages of development, our compounds have characteristics which may be advantageous for clinical use. The Lixte compounds also have broad anti-cancer activity but in addition have 1) potential for the treatment of neurodegenerative diseases, for which Lixte recently announced a USPTO patent approval, 2) activity (LB-205) against the lysosomal storage disease, Gaucher Disease, as recently reported in the Proceedings of the National Academy of Science, USA (Dec. 27 2011; 108:21200-5) and 3) curative anti-fungal activity applied topically (LB-201) against the most common skin fungal infections of humans and domestic animals in guinea pig models. As Lixte is predominantly focused on cancer treatment, it is seeking to license the non-neoplastic activities of its proprietary HDACi."
Dr. Kovach continued, "Lixte's primary goal at present is bringing its lead anti-cancer compound, LB-100, into Phase I trial. We believe this inhibitor of serine/threonine phosphatase has the potential to be first-in-class and to have wide applicability for the treatment of diverse cancers. LB-100 has completed pre-clinical toxicology and formulation with an anticipated IND submission for FDA approval of a Phase I trial this spring."
About Lixte Biotechnology Holdings, Inc.
Lixte is a cancer drug discovery company, combining selection of novel targets from the medicinal chemistry and molecular biology literature with innovative synthetic chemistry to develop new potentially more effective anti-cancer drugs. It has l
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved